Trial Recruitment Closes On Novo’s Next Big Semaglutide Bet: Alzheimer’s Disease
Twin EVOKE Studies Aim To Prove Neurological Benefits
Semaglutide has become a game-changer in type 2 diabetes and overweight patients, but Novo Nordisk is hoping to prove it can also slow cognitive decline in Alzheimer’s disease. It’s a long shot, but two large Phase III studies are now well underway to show just that.
You may also be interested in...
Lilly expects US approval of the anti-amyloid therapy by the end of the year. Full Phase III data were detailed at AAIC.
Genentech is broadening its stake in the protein degradation field, following BMS and Merck & Co into molecular glue drugs.
RayzeBio's IPO and Genentech's first buy-in into the field show a wave of next-generation companies hoping to expand the radiopharmaceutical field.